title: Schnitzler's syndrome improvement after anti-TNF-alpha therapy.
authors.forename: Nádia Emi
authors.initials: NE
authors.lastname: Aikawa
authors.forename: Clovis Artur A
authors.initials: CA
authors.lastname: Silva
authors.forename: Eloísa
authors.initials: E
authors.lastname: Bonfá
authors.forename: Jozélio Freire de
authors.initials: JF
authors.lastname: Carvalho
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003622:Dapsone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D019873:Schnitzler Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D003622:Dapsone; D000068879:Adalimumab; D000068800:Etanercept; D011241:Prednisone